A Phase 1/2 study of Nivolumab and Hydroxychloroquine in Advanced Melanoma
Active, Not Recruiting Phase 1,Phase 2 NCT04464759
Study Description
A Clinical Trial Evaluating the Safety and Efficacy of Combining Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Patients with Advanced Melanoma
Study Details
- Registry ID:
- NCT04464759
- Conditions:
- Melanoma
- Phase:
- Phase 1,Phase 2
- Target Enrollment:
- 41 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.